tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Tissue Regenix Celebrates Sustained Growth in H1 2024

Tissue Regenix Celebrates Sustained Growth in H1 2024

Tissue Regenix (GB:TRX) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Tissue Regenix Group PLC reports a 16% increase in revenues to $16.4 million in H1 2024, with significant growth in their regenerative medical devices driven by BioRinse and dCELL technology platforms. The company has doubled its adjusted EBITDA profit to $1.1 million and maintained a solid cash position, while achieving its eighth consecutive period of growth. The successful results are attributed to strategic growth initiatives, including the expansion of its San Antonio facility, expected to complete in 2025.

For further insights into GB:TRX stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1